Endometrial Transitional Cell Carcinoma

Endometrial Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1
Recruiting: 0
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	active not recruiting	Phase 2	798	National Cancer Institute (NCI)NIH	2	Jun 17, 2026	clinicaltrials
NCT01642082	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	Phase 2	28	Gynecologic Oncology GroupNETWORK	1	Mar 13, 2018	clinicaltrials